Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer

相关推荐

• Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer
• Programmed cell death ligand-1 （PD-L1） expression by immunohistochemistry： could it be predictive and/or prognostic in non-small cell lung cancer？
• Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer
• Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors
• Immunotherapy in non-small cell lung cancer: advancements and challenges

同分类资源 更多

• [医药卫生] 帕金森病与炎性肠病在遗传学和肠道微生物方面的关联研究进展
• [医药卫生] 肌萎缩侧索硬化与肠道菌群相关性的研究进展
• [医药卫生] 单核苷酸多态性对阿尔茨海默病药物疗效影响的研究进展
• [医药卫生] 放射性认知功能障碍的机制及治疗研究进展
• [医药卫生] 伴中央颞区棘波的儿童良性癫痫患儿认知功能障碍影响因素的研究进展

相关关键词